EXecutive: XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS) in the Treatment of the Specific Setting of Patients With Multi-Vessel Coronary Artery Disease.
Phase of Trial: Phase IV
Latest Information Update: 12 Nov 2018
At a glance
- Drugs Everolimus; Paclitaxel
- Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
- Focus Therapeutic Use
- Acronyms EXecutive
- Sponsors Abbott Laboratories
- 10 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Sep 2009 Planned end date changed from 1 Sep 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.
- 03 Jan 2008 Added trial centre from NCT last updated 3 Jan 2008.